Tumor necrosis factor-α, insulin resistance, the lipoprotein metabolism and obesity in humans;El factor de necrosis tumoral-α, la resistencia a la insulina, el metabolismo de lipoproteínas y la obesidad en humanos

Nutricion Hospitalaria

Volumn 27, Issue 6, 2012, Pages 1751-1757

  Ramírez Alvarado, María Matilde ^a   Sanchez Roitz C ^b  

^a UNIVERSIDAD DE CARABOBO   (Venezuela)

^b Centro Medico Dr Rafael Guerra Mendez   (Venezuela)

Author keywords

Cholesterol; Insulin resistance; Lipoproteins; Tumor necrosis factor and alpha;

Indexed keywords

LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL; DOG; HUMAN; INSULIN RESISTANCE; LIVER CELL; META ANALYSIS; METABOLISM; MUSCLE CELL; OBESITY; PHYSIOLOGY; RABBIT; RAT;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; DOGS; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; MUSCLE CELLS; OBESITY; RABBITS; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874684012     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2012.27.6.6004     Document Type: Article

References (56)

1. Caballero B. A nutrition paradox-underweight and obesity in developing countries. N Engl J Med 2005; 352: 1514-1516.
2. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J et al. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
3. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006; 17: 901-909.
4. Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature. Eur J Clin Nutr 2010; 64: 16-22.
5. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
6. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
7. Wellen EW, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788.
8. Yu YH, Ginsberg H. Adipocyte signaling and lipid homeostasis. Sequelae of insulin-resistant adipose tissue. Circ Res 2005; 96: 1042-1052.
9. Mohamed-Ali B, Gooddrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-6, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
10. Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab 2001; 86: 1267-1273.
11. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-BBin human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
12. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
13. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
14. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.
15. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-1319.
16. Salans LB, Cushman SW, Weismann RE. Studies of human adipose tissue. Adipose cell size and number in nonobese and obese patients. J Clin Invest 1973; 52: 929-941.
17. Cancello R, Clément K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 2006; 113: 1141-1147.
18. Bouloumié A, Curat CA, Sengenès C, Lolmède K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005; 8: 347-354.
19. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-52.
20. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993; 9: 317-43.
21. Pennica D, Nedwin G, Hayflick JS, Seeburg PH, Derynck R, Palladino MA et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724-9.
22. Hotamisligil GS, Shargill NS, Spieeglman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
23. Rotter V, Nagaev I, Smith U. Interlekin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulinresistant subjects. J Biol Chem 2003; 278: 45777-45784.
24. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Janowska J, Zurakowski A. Serum concentrations of nitric oxide, tumor necrosis factor (TNF)-alpha and TNF soluble receptors in women with overweight and obesity. Metabolism 2004; 53: 1268-1273.
25. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907-2910.
26. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor expression. Gut 2010; 59: 1259-1264.
27. Fernández-Veledo S, Vila-Bedmar R, Nieto-Vazquez I, Lorenzo M. c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J Clin Endocrinol Metab 2009; 94: 3583-3593.
28. Gupta D, Varma S, Khandelwal RL. Long-term effects of tumor necrosis factor-alpha treatment on insulin signaling pathway in HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB. J Cell Biochem 2007; 100: 593-607.
29. Bouzakri K, Zierath JR. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 2007; 282: 7783-7789.
30. Hauner H, Petruschke T, Russ M, Röhrig K, Eckel J. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995; 38: 764-771.
31. Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A et al. Involvement of TNF-alpha in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia 2009; 52: 932-940.
32. Zubelewicz-SzkodziDska B, Szkodzi ski J, Danikiewicz A, Romanowski W, BBazelonis A, Muc-Wierzgon M et al. Effects of simvastatin on pro-inflammatory cytokines in patients with hypercholesterolemia. Kardiol Pol 2003; 59: 465-474.
33. Jovinge S, Hamsten A, Tornvall P, Proudler A, Båvenholm P, Ericsson CG et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998; 47: 113-118.
34. Gokalp D, Tuzcu A, Bahceci M, Arikan S, Pirinccioglu AG, Bahceci S. Levels of proinflammatory cytokines and hs-CRP in patients with homozygous familial hypercholesterolaemia. Acta Cardiol 2009; 64: 603-609.
35. Pauciullo P, Gentile M, Marotta G, Baiano A, Ubaldi S, Jossa F et al. Tumor necrosis factor-alpha is a marker of familial combined hyperlipidemia, independently of metabolic syndrome. Metabolism 2008; 57: 563-568.
36. Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-305.
37. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33: 2440-2446.
38. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-1507.
39. Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006; 35: 107-111.
40. Marketou ME, Zacharis EA, Nikitovic D, Ganotakis ES, Parthenakis FI, Maliaraki N et al. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology 2006; 57: 211-218.
41. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004; 95: 185-191.
42. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC et al. Atorvastatin reduces proinflammatory markers in hypercholestherolemic patients. Atherosclerosis 2004; 177: 161-166.
43. Fried SK, Zechner R. Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J Lipid Res 1989; 30: 1917-1923.
44. Hauner H, Petruschke T, Russ M, Röhrig K, Eckel J. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995; 38: 764-771.
45. Bulló M, García-Lorda, Peinado-Onsurbe J, Hernández M, Del Castillo D, Argilés JM et al. TNFalpha expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis. Int J Obes Relat Metab Disord 2002; 26: 652-658.
46. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.
47. Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NC, Mooradian AD. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Biochim Biophys Acta 2003; 1623: 120-128.
48. Song H, Saito K, Fujigaki S, Noma A, Ishiguro H, Nagatsu T et al. IL-1 beta and TNF-alpha suppress apolipoprotein (apo) E secretion and apo A-I expression in HepG2 cells. Cytokine 1998; 10: 275-280.
49. Mehran M, Seidman E, Marchand R, Gurbindo C, Levy E. Tumor necrosis factor-alpha inhibits lipid and lipoprotein transport by Caco-2 cells. Am J Physiol 1995; 269: G953-G960.
50. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22: 347-351.
51. Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000; 106: 1263-1270.
52. Field FJ, Watt K, Mathur SN. TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. J Lipid Res 2010; 51: 1407-1415.
53. De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J Biol Chem 2001; 276: 30708-30716.
54. Memon RA, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. potential role of hepatocyte nuclear factor-1. J Biol Chem 2001; 276: 30118-30126.
55. Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 2008; 48: 770-781.
56. Liao W, Florén CH. Upregulation of low density lipoprotein receptor activity by tumor necrosis factor, a process independent of tumor necrosis factor-induced lipid synthesis and secretion. Lipids 1994; 29: 679-684.